TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Randomized Controlled Trial to Evaluate the Effectiveness of the Two Different Appliances in the Treatment of Class II Division 1 Malocclusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a Class II malocclusion as defined by British Standards Institute classification.~* Overjet greater than 6mm~* Aged 10-14 years~* Clinical examination indicates a functional appliance is not contraindicated~Exclusion Criteria:~* Orthognathic treatment is required or there is a strong indication it will be required in the future~* Possession of a craniofacial anomaly~* Previous orthodontic treatment and/or premolar extraction~* Hypodontia of more than one teeth in any quadrant excluding third molars~* Inadequate oral hygiene

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Functional appliance-Dynamax (Type: EXPERIMENTAL): None
- Functional appliance- twin block (Type: OTHER): Conventional treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed squamous cell carcinoma of the larynx (preferably tumours located within the bone structures of the larynx)~* Decision of primary surgery with curative intent made by the multidisciplinary group of head and neck tumours at Leuven University Hospital~* Karnofsky performance status ≥70%~* Age ≥ 18 years old~* Gender: Male - Female~* Informed consent obtained, signed and dated before specific protocol procedures~Exclusion Criteria:~* Prior irradiation to the head and neck region~* Medical contraindications for any of the planned investigations~* Distant metastases~* Pregnant or lactating women~* Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study~* Patient unlikely to comply with the protocol, i.e. uncooperative attitude, inability to return for follow-up visits, and unlikely to complete the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women~* 18-35 years old~* Current collegiate or professional swimmer~* Currently training at least 300 minutes per week~* Self-reported to be healthy~Exclusion Criteria:~* Not within defined age range~* Current diagnosis of or using medication for:~  * Severe allergies~ * Asthma~ * Exercise-induced asthma~ * Exercise-induced bronchoconstriction~* Pulmonary function test considered to be abnormal (defined as forced vital capacity (FVC) \<80% of predicted, forced expiratory volume in one second (FEV1) \<80% predicted, and/or FEV1/FVC ratio \>5% of the predicted ratio)~* Hypertension during screening (systolic blood pressure \>139 or diastolic blood pressure \>89)~* Current tobacco or electronic cigarette use or consistent use within the last 2 years~* A contraindication for use of nedocromil sodium:~  * Previous adverse reaction to nedocromil sodium or a similar medication~ * Use of fast-acting, inhaled insulin~* A contraindication for use of cetirizine HCl:~  * Previous adverse reaction to cetirizine HCl or a similar medication~ * Allergy to the food additives E218 or E216~ * An intolerance to or inability to absorb some sugars, such as lactose or sorbitol~ * Liver or kidney failure~ * Epilepsy or similar condition~ * A condition that makes urinating difficult~ * Use of midodrine or ritonavir~* Are pregnant or could possibly be pregnant by self-report~* Subjects with current, irregular menstrual cycles (amenorrhea) or who had irregular menstruation patterns for greater than one year~* People who answer 'yes' to any of the pre-participation screening questions on page one of the PAR-Q+ questionnaire.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Experimental group (Type: EXPERIMENTAL): This subset of 12 individuals will complete all experimental study visits, and will ingest either 1) a placebo pill and placebo inhaler contents or 2) a cetirizine HCl pill (10 mg) and placebo inhaler contents in a randomized order and double-blind fashion.
- Selection pool (Type: NO_INTERVENTION): Twenty-four total individuals will be recruited for the initial portion of the study, and the aforementioned 12 (6 men, 6 women) will be a subset of the initial 24. The other 12 participants will not take part in further study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female \> 40 years of age.~* Pt with expected stay in hospital 6 days or \>, with expectation to be bedridden for \> 4 days.~* Pts admitted to the MICU, Regional Heart Units of LV-MHC~Exclusion Criteria:~* Surgical primary admission diagnosis~* Recent surgery within the past 12 weeks~* Planned surgery on the current admission~* Pregnancy~* Vent-dependent respiratory failure requiring intubation for \>24 hours.~* Known current DVT or PE prior to enrollment in study.~* Creatinine clearance \< 30 mL/min (calculated by the Cockcroft-Gault method) in a well-hydrated patient.~* Hx of prior or current lower upper or lower GI bleed.~* Platelet count \< 100,000 per cubic millimeter~* Current or prior anticoagulation within the prior 48 hours, excluding a single dose \&lor 24 hour period of prophylactic agent~* Bacterial endocarditis.~* Hemophilia~* Hypersensitivity to aspirin.~* Hypersensitivity to Arixtra or Lovenox~* Hx of hemorrhagic or ischemic stroke \< 3 months prior to enrolling~* Hematocrit \< 28%.~* SBP \>200 mmHg or DBP \>120 mmHg~* Positive for occult blood in stool.~* Admission to hospital for \> 48 hours prior to randomization~* Documented congenital or acquired bleeding disorder~* Indwelling intrathecal or epidural catheter~* Life expectancy \< 30 days~* Inability to have a flu assessment post-discharge from the hospital

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arixtra (Fondaparinox) 2.5 mg SC Daily (Type: ACTIVE_COMPARATOR): Arixtra (Fondaparinox) 2.5 mg SC Daily
- Lovenox 40mg SC Daily (Type: ACTIVE_COMPARATOR): Lovenox 40mg SC Daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy of a Biological Implant to Reinforce Overlapping Sphincter Repair Versus Overlapping Sphincter Repair Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age 18 years or older~* fecal incontinence due to an anterior defect in the external anal sphincter or both external and internal anal sphincter muscles~* Fecal incontinence severity score of 10 or more~* Fecal incontinence episodes of 4 or more over a 2 week period~Exclusion Criteria:~* History of diabetes~* History of allergy to porcine derivatives~* History of infection in the anal area (abscess, fistula)~* History of inflammatory bowel disease~* History of hidradenitis suppurativa~* History of immunosuppression~* History of HIV positivity~* History of radiation to the study site within the last 12 months~* Patients who cannot travel to keep follow up appointments~* Patients who are prisoners~* Patients who are mentally handicapped~* Patients who are pregnant or plan to become pregnant during the study period, or who are currently breastfeeding~* Patients with significant posterior pelvic organ prolapse and who would be candidates for concomitant treatment.~* Patients with a FIQL baseline score of ≤ 4~* Patients participating in another clinical trial for the same indication~* Patients unwilling to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biodesign Tissue Repair Graft (Type: EXPERIMENTAL): Biodesign Tissue Repair Graft
- Overlapping Sphincter Repair (Type: ACTIVE_COMPARATOR): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients:~* with schizophrenia being treated with olanzapine, risperidone, or quetiapine for at least 3 months~* with diagnosis of metabolic syndrome~* not treated for 1 of the parameters of metabolic syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediated Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, age 6 months or older~2. Affirmation of participant's informed consent or legally authorized representative (LAR)'s willingness to provide informed consent with signature confirmation before any study-related activities. (Study-related activities are any procedures that would not have been performed during normal clinical management of the participant.) The participant (if a minor) must also be willing to give written informed assent (if able) if the minor is within the age groups 7 to 11 years old and 12 to 17 years old.~3. Confirmed CFI deficiency during the screening study, CFI-001, with a disease that is associated with an absence or deficiency in CFI~4. Stated willingness of the participant to comply with all study procedures (including multiple blood draws) and availability for the duration of the study~5. Stated willingness of the participant (or LAR) to allow access to his/her medical records with the purpose of assessing disease status and progression during his/her participation in the study~Exclusion Criteria:~1. Participation in an interventional clinical study within the previous 30 days prior to screening or within ≤5 half-lives of the investigational drug, whichever is longer~2. Having a major concurrent non-CFI-related disease that prevents the assessment of the natural course of the CFI deficiency disease~3. Having a medical, psychosocial, or familial issues that might prevent full participation and cooperation with the procedures and requirements of the clinical study as determined by the potential participant/guardian and physician investigator

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is \> 18 years of age~2. Histologically or cytologically confirmed diagnosis of breast adenocarcinoma ≥ 3 cm determined by ultrasound, or locally advanced breast cancer (LABC: T3-4NxMx or TxN2-3Mx)~3. HER2-positiv breast cancer first recurrence~4. HER2-positiv breast cancer primary metastatic~5. HER2 status has been determined on biopsy material from the primary tumour and found to be HER2-positive, defined as a DAKO HercepTest™ score of 3+ or else 2+ and FISH positive~6. \[18F\]FDG PET/ceCT performed within 7 days before administration of IMP~7. ECOG performance status of =\< 2~8. Hematological, liver and renal function test results within the following limits:~   * White blood cell count: \> 2.0 x 10\^9/L~  * Haemoglobin: \> 5.0 mmol/L~  * Platelets: \> 50.0 x 10\^9/L~  * ALT, ALP: =\< 3 times Upper Limit of Normal~  * Bilirubin =\< 2.0 times Upper Limit of Normal~  * Serum creatinine: Within Normal Limits~9. A negative pregnancy test (serum beta-HCG) at screening for all subjects of childbearing potential~10. Subject is capable to undergo the diagnostic investigations to be performed in the study~11. Informed consent~Exclusion Criteria:~* 1. Known hypersensitivity to Dotarem® 2. Active known autoimmune disease or history of autoimmune disease 3. Active serious infection according to investigator evaluation 4. Known HIV positive or chronically active hepatitis B or C 5. Administration of other investigational medicinal product within 30 days of screening 6. Pregnant or breast-feeding 7. Women capable of childbearing not using a sufficient non-hormonal method of birth control 8. Other primary malignancies (including primary brain tumors) within the last 5 years before inclusion, with exception of sufficiently treated in situ carcinoma of the cervix, squamous carcinoma of the skin or sufficiently controlled limited basal cell carcinoma of the skin 9. Signs of any other disease, metabolic or psychological dysfunction, findings at physical examination or laboratory findings, which give reasonable suspicion of a disease or condition that would contraindicate use of the IMP, could influence the patient's compliance with the study routines or involves an increased risk for treatment-related complications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [68Ga]ABY-025 PET imaging (Type: EXPERIMENTAL): Radiolabeled \[68Ga\]ABY-025

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: VALIANT CAPTIVIA Post-market Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Age ≥ 18 years or minimum age as required by local regulations~* Indication for surgical repair of thoracic aortic aneurysms and/or thoracic aortic dissections with an thoracic endovascular stent graft in accordance with the applicable guidelines on endovascular interventions and the Instructions for Use of the Valiant Captivia Thoracic Stent Graft System~* Signed consent form ('Patient informed consent form' or 'Patient Data Release Authorization Form')~* Intention to implant the Valiant Captivia Thoracic Stent Graft System or having implanted the system within the last 3 months before subject enrollment~* Willingness and ability to comply with the CIP~Exclusion criteria~* High probability of non-adherence to physician's follow-up requirements~* Participation in concurrent interventional trial which may confound study results~* Prior implantation of a thoracic stent graft

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients undergoing TEVAR (Type: None): Those with a thoracic aortic aneurysm/dissection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Long Term Performance and Safety of the Knee Prosthesis (HLS KneeTec Deep Dish)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 - 80 years old at the time of the surgery~* Implanted with an HLS KneeTec Deep Dish TKP according to the Instructions for Use (IFU) after the 1st of february, 2017~* Patients agree to consent to collect data from their medical records and agree to answer questionnaires for the purposes of the study.~Exclusion Criteria:~* Patients under guardianship and/or those who, according to the investigator or his delegated research team, will not be able to comply with the study procedures. (e.g. illiteracy, recent psychotic or manic disorders and/or inability to comply with routine follow-up visits.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patient with knee arthroplasty (Type: None): patient with HLS KneeTec Deep Dish prosthesis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed non-metastatic infiltrating carcinoma of the breast.~2. HER-2 amplified (FISH +) determination in 2004 or thereafter.~3. ECOG performance status 0-2.~4. Patients 18 years of age or older.~5. HER-2 status is determined by FISH test.~6. The following criteria are applicable to the trastuzumab treatment group:~   * Normal LVEF as determined by ECHO or MUGA. If baseline LVEF \> 75%, then LVEF shall be repeated to determine if falsely elevated.~  * Adequate bone marrow function as indicated by the following: ANC \>1500/mL, Platelets \>/=100,000/mL, Hemoglobin \>9 g/dL~  * Adequate renal function,as indicated by serum creatinine \</= 1.5 x ULN~  * Adequate liver function, as indicated by total bilirubin \</= 1.5 x ULN~  * AST and ALT \< 2 x ULN unless related to primary disease.~  * If female of childbearing potential, pregnancy test (blood or urine) is negative and she agrees to use effective birth control method for the duration of the study.~7. Signed informed consent has been obtained.~Exclusion Criteria:~1. Non-confirmed HER-2 positive by FISH infiltrating carcinoma of the breast.~2. Evidence of metastatic disease.~3. Previous trastuzumab treatment.~4. Concurrent anticancer treatment other than hormonal agents (tamoxifen, aromatase inhibitors) or radiotherapy.~5. Patient with history of or active cardiac disease, including cardiomyopathy, congestive heart failure, prior myocardial infarction, or arrhythmia.~6. Symptomatic intrinsic lung disease resulting in dyspnea at rest.~7. Concurrent life-limiting disease with a life expectancy of less than one year.~8. Pregnancy, nursing women, and fertile women who do not practice birth control.~9. Inability to give informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient, regardless of gender, aged 18 to 80 years.~* Well-established diagnostic criteria of the Idiopathic Pulmonary Fibrosis (IPF) as ATA/ERS/JRS/ALAT 2011.~* Ability to obtain a sample of sputum or oropharyngeal washing.~* Forced Vital Capacity (FVC) above 50% from the theoretical value expected.~* Patient compliance or legal guardian to participate in this study by signing the informed consent.~Exclusion Criteria:~* Allergy / hypersensitivity or known gastrointestinal intolerance to cotrimoxazole.~* Use of immunosuppressants or corticosteroids in the previous 90 days at baseline.~* Exacerbation of IPF and / or pneumonia in the 90 days prior to baseline.~* Presence of autoimmune diseases or asthma.~* Patients with other significant diseases other than IPF. It is considered significant disease any disease or condition that, in the investigator's opinion, may jeopardize the patient's health participating in the study or influence the results of the study or the patient's ability to participate in the study.~* Pregnant or lactating or of childbearing potential not using medically approved contraceptive methods at least three months before or during trial.~* Participation in another trial with an investigational drug within 30 days or six half-lives (the larger of the two) above the baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cotrimoxazole (Type: EXPERIMENTAL): Sulfamethoxazole 400 mg. + trimethoprim 80 mg. weight-adjusted
- Placebo (Type: PLACEBO_COMPARATOR): Identical capsules to cotrimoxazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy